KR20140006898A - 결장암 유전자 발현 시그니처 및 이용 방법 - Google Patents
결장암 유전자 발현 시그니처 및 이용 방법 Download PDFInfo
- Publication number
- KR20140006898A KR20140006898A KR1020137021973A KR20137021973A KR20140006898A KR 20140006898 A KR20140006898 A KR 20140006898A KR 1020137021973 A KR1020137021973 A KR 1020137021973A KR 20137021973 A KR20137021973 A KR 20137021973A KR 20140006898 A KR20140006898 A KR 20140006898A
- Authority
- KR
- South Korea
- Prior art keywords
- colon cancer
- nucleic acid
- transcripts
- sample
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010009944 Colon cancer Diseases 0.000 title claims abstract description 272
- 230000014509 gene expression Effects 0.000 title claims abstract description 257
- 238000000034 method Methods 0.000 title claims abstract description 255
- 208000029742 colonic neoplasm Diseases 0.000 title claims abstract description 249
- 108700019961 Neoplasm Genes Proteins 0.000 title description 6
- 102000048850 Neoplasm Genes Human genes 0.000 title description 6
- 238000004393 prognosis Methods 0.000 claims abstract description 46
- 210000001072 colon Anatomy 0.000 claims abstract description 27
- 238000002493 microarray Methods 0.000 claims abstract description 26
- 238000011226 adjuvant chemotherapy Methods 0.000 claims abstract description 15
- 238000002271 resection Methods 0.000 claims abstract description 6
- 239000000523 sample Substances 0.000 claims description 278
- 150000007523 nucleic acids Chemical class 0.000 claims description 154
- 108090000623 proteins and genes Proteins 0.000 claims description 138
- 102000039446 nucleic acids Human genes 0.000 claims description 119
- 108020004707 nucleic acids Proteins 0.000 claims description 119
- 238000011282 treatment Methods 0.000 claims description 60
- 230000004083 survival effect Effects 0.000 claims description 36
- 239000002773 nucleotide Substances 0.000 claims description 34
- 125000003729 nucleotide group Chemical group 0.000 claims description 33
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 30
- 230000003321 amplification Effects 0.000 claims description 29
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 26
- 238000001514 detection method Methods 0.000 claims description 26
- 230000004044 response Effects 0.000 claims description 25
- 230000000295 complement effect Effects 0.000 claims description 23
- 239000002299 complementary DNA Substances 0.000 claims description 20
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 18
- 230000007774 longterm Effects 0.000 claims description 18
- 238000003745 diagnosis Methods 0.000 claims description 16
- 108091006298 SLC2A3 Proteins 0.000 claims description 14
- 102100022722 Solute carrier family 2, facilitated glucose transporter member 3 Human genes 0.000 claims description 14
- 238000002512 chemotherapy Methods 0.000 claims description 14
- 102100033887 Arylsulfatase D Human genes 0.000 claims description 12
- 101000925559 Homo sapiens Arylsulfatase D Proteins 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 11
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 10
- 101001011441 Homo sapiens Interferon regulatory factor 4 Proteins 0.000 claims description 10
- 101001131670 Homo sapiens PWWP domain-containing DNA repair factor 3A Proteins 0.000 claims description 10
- 101000836994 Homo sapiens Sigma non-opioid intracellular receptor 1 Proteins 0.000 claims description 10
- 102100030126 Interferon regulatory factor 4 Human genes 0.000 claims description 10
- 102100028656 Sigma non-opioid intracellular receptor 1 Human genes 0.000 claims description 10
- 230000000692 anti-sense effect Effects 0.000 claims description 10
- 238000003499 nucleic acid array Methods 0.000 claims description 10
- 238000010195 expression analysis Methods 0.000 claims description 9
- 101000972284 Homo sapiens Mucin-3A Proteins 0.000 claims description 8
- 101001120760 Homo sapiens Olfactomedin-4 Proteins 0.000 claims description 8
- 101000692683 Homo sapiens RING finger protein 39 Proteins 0.000 claims description 8
- 102100022497 Mucin-3A Human genes 0.000 claims description 8
- 102100026071 Olfactomedin-4 Human genes 0.000 claims description 8
- 102100026465 RING finger protein 39 Human genes 0.000 claims description 8
- 102100032424 B-cell CLL/lymphoma 9-like protein Human genes 0.000 claims description 7
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 claims description 7
- 101000798491 Homo sapiens B-cell CLL/lymphoma 9-like protein Proteins 0.000 claims description 7
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 claims description 7
- 101000913082 Homo sapiens IgGFc-binding protein Proteins 0.000 claims description 7
- 101000609959 Homo sapiens Protein piccolo Proteins 0.000 claims description 7
- 102100026103 IgGFc-binding protein Human genes 0.000 claims description 7
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 7
- 102100039154 Protein piccolo Human genes 0.000 claims description 7
- 108091006302 SLC2A14 Proteins 0.000 claims description 7
- 102100039672 Solute carrier family 2, facilitated glucose transporter member 14 Human genes 0.000 claims description 7
- 239000002853 nucleic acid probe Substances 0.000 claims description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 6
- 238000001574 biopsy Methods 0.000 claims description 6
- 239000012188 paraffin wax Substances 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 101001064542 Homo sapiens Liprin-beta-1 Proteins 0.000 claims description 5
- 101000826406 Homo sapiens Sulfotransferase 1C2 Proteins 0.000 claims description 5
- 101000585332 Homo sapiens Sulfotransferase 1C4 Proteins 0.000 claims description 5
- 102100031961 Liprin-beta-1 Human genes 0.000 claims description 5
- 102100023985 Sulfotransferase 1C2 Human genes 0.000 claims description 5
- 230000002441 reversible effect Effects 0.000 claims description 5
- 230000005855 radiation Effects 0.000 claims description 4
- 229960002685 biotin Drugs 0.000 claims description 3
- 235000020958 biotin Nutrition 0.000 claims description 3
- 239000011616 biotin Substances 0.000 claims description 3
- 230000001747 exhibiting effect Effects 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 147
- 201000011510 cancer Diseases 0.000 abstract description 67
- 230000004547 gene signature Effects 0.000 abstract description 8
- 108020004414 DNA Proteins 0.000 description 671
- 241000282414 Homo sapiens Species 0.000 description 643
- 210000001519 tissue Anatomy 0.000 description 115
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 103
- 108020004999 messenger RNA Proteins 0.000 description 46
- 210000004027 cell Anatomy 0.000 description 45
- 108091034117 Oligonucleotide Proteins 0.000 description 36
- 238000012549 training Methods 0.000 description 34
- 102000004169 proteins and genes Human genes 0.000 description 33
- 238000003752 polymerase chain reaction Methods 0.000 description 32
- 238000009396 hybridization Methods 0.000 description 30
- 239000000047 product Substances 0.000 description 30
- 238000004458 analytical method Methods 0.000 description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 27
- 230000001965 increasing effect Effects 0.000 description 24
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 23
- 238000001356 surgical procedure Methods 0.000 description 23
- 238000003556 assay Methods 0.000 description 22
- 230000000875 corresponding effect Effects 0.000 description 21
- 239000000463 material Substances 0.000 description 21
- 238000003908 quality control method Methods 0.000 description 20
- 238000012360 testing method Methods 0.000 description 20
- 201000010099 disease Diseases 0.000 description 19
- 102000040430 polynucleotide Human genes 0.000 description 19
- 108091033319 polynucleotide Proteins 0.000 description 19
- 239000002157 polynucleotide Substances 0.000 description 18
- 238000003491 array Methods 0.000 description 17
- 238000002790 cross-validation Methods 0.000 description 17
- 238000010200 validation analysis Methods 0.000 description 17
- 230000008569 process Effects 0.000 description 16
- 239000007787 solid Substances 0.000 description 16
- 230000006870 function Effects 0.000 description 15
- 238000011160 research Methods 0.000 description 15
- 239000000758 substrate Substances 0.000 description 15
- 238000010240 RT-PCR analysis Methods 0.000 description 14
- 230000027455 binding Effects 0.000 description 14
- -1 co-factors Substances 0.000 description 14
- 238000010837 poor prognosis Methods 0.000 description 14
- 230000008901 benefit Effects 0.000 description 13
- 230000015556 catabolic process Effects 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 13
- 238000006731 degradation reaction Methods 0.000 description 13
- 238000011161 development Methods 0.000 description 13
- 238000007901 in situ hybridization Methods 0.000 description 11
- 238000013518 transcription Methods 0.000 description 11
- 230000035897 transcription Effects 0.000 description 11
- 238000000018 DNA microarray Methods 0.000 description 10
- 210000004881 tumor cell Anatomy 0.000 description 10
- 230000008859 change Effects 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 206010027476 Metastases Diseases 0.000 description 8
- 239000004743 Polypropylene Substances 0.000 description 8
- 238000013461 design Methods 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 238000009826 distribution Methods 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 8
- 229920001155 polypropylene Polymers 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 238000011223 gene expression profiling Methods 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 230000009401 metastasis Effects 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 238000004422 calculation algorithm Methods 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 231100000517 death Toxicity 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 238000010369 molecular cloning Methods 0.000 description 6
- 238000010606 normalization Methods 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 108020004635 Complementary DNA Proteins 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 5
- 206010061819 Disease recurrence Diseases 0.000 description 5
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000002596 correlated effect Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 210000001165 lymph node Anatomy 0.000 description 5
- 239000002751 oligonucleotide probe Substances 0.000 description 5
- 239000013610 patient sample Substances 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 230000003827 upregulation Effects 0.000 description 5
- 238000000636 Northern blotting Methods 0.000 description 4
- 108020004566 Transfer RNA Proteins 0.000 description 4
- 238000009098 adjuvant therapy Methods 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 238000002869 basic local alignment search tool Methods 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229940127089 cytotoxic agent Drugs 0.000 description 4
- 230000003828 downregulation Effects 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000007850 in situ PCR Methods 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 238000010208 microarray analysis Methods 0.000 description 4
- 238000012775 microarray technology Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229920000620 organic polymer Polymers 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 108020004418 ribosomal RNA Proteins 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000011269 treatment regimen Methods 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 108700024394 Exon Proteins 0.000 description 3
- 108091092195 Intron Proteins 0.000 description 3
- 108700011259 MicroRNAs Proteins 0.000 description 3
- 238000002123 RNA extraction Methods 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000013528 artificial neural network Methods 0.000 description 3
- 230000031018 biological processes and functions Effects 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 238000010804 cDNA synthesis Methods 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 230000009826 neoplastic cell growth Effects 0.000 description 3
- 238000003909 pattern recognition Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000004043 responsiveness Effects 0.000 description 3
- 238000003196 serial analysis of gene expression Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000005382 thermal cycling Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 108020004463 18S ribosomal RNA Proteins 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 241000212384 Bifora Species 0.000 description 2
- 208000019399 Colonic disease Diseases 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 238000010802 RNA extraction kit Methods 0.000 description 2
- 101100029566 Rattus norvegicus Rabggta gene Proteins 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 102000039471 Small Nuclear RNA Human genes 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 239000003181 biological factor Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000005081 chemiluminescent agent Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000010230 functional analysis Methods 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000011221 initial treatment Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 238000010841 mRNA extraction Methods 0.000 description 2
- 238000010801 machine learning Methods 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 238000007899 nucleic acid hybridization Methods 0.000 description 2
- 238000002515 oligonucleotide synthesis Methods 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 238000001558 permutation test Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000000513 principal component analysis Methods 0.000 description 2
- 230000004557 prognostic gene signature Effects 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000007637 random forest analysis Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000004055 small Interfering RNA Substances 0.000 description 2
- 108091029842 small nuclear ribonucleic acid Proteins 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- PZWQOGNTADJZGH-SNAWJCMRSA-N (2e)-2-methylpenta-2,4-dienoic acid Chemical compound OC(=O)C(/C)=C/C=C PZWQOGNTADJZGH-SNAWJCMRSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- 240000005020 Acaciella glauca Species 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 244000148064 Enicostema verticillatum Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108091092566 Extrachromosomal DNA Proteins 0.000 description 1
- 238000001134 F-test Methods 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 108700010013 HMGB1 Proteins 0.000 description 1
- 101150021904 HMGB1 gene Proteins 0.000 description 1
- 102100037907 High mobility group protein B1 Human genes 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 238000003657 Likelihood-ratio test Methods 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 108091027974 Mature messenger RNA Proteins 0.000 description 1
- 208000032818 Microsatellite Instability Diseases 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 239000012807 PCR reagent Substances 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091036407 Polyadenylation Proteins 0.000 description 1
- 239000005062 Polybutadiene Substances 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 208000006994 Precancerous Conditions Diseases 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 101150088517 TCTA gene Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 238000011256 aggressive treatment Methods 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000011948 assay development Methods 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229920006378 biaxially oriented polypropylene Polymers 0.000 description 1
- 239000011127 biaxially oriented polypropylene Substances 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 238000009096 combination chemotherapy Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- HQQADJVZYDDRJT-UHFFFAOYSA-N ethene;prop-1-ene Chemical group C=C.CC=C HQQADJVZYDDRJT-UHFFFAOYSA-N 0.000 description 1
- 229920006226 ethylene-acrylic acid Polymers 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000013115 immunohistochemical detection Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000011901 isothermal amplification Methods 0.000 description 1
- 238000001499 laser induced fluorescence spectroscopy Methods 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004879 molecular function Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000009099 neoadjuvant therapy Methods 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 230000000683 nonmetastatic effect Effects 0.000 description 1
- 230000008481 normal tissue growth Effects 0.000 description 1
- 238000001216 nucleic acid method Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- 238000003068 pathway analysis Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 238000000206 photolithography Methods 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002493 poly(chlorotrifluoroethylene) Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920002857 polybutadiene Polymers 0.000 description 1
- 229920001748 polybutylene Polymers 0.000 description 1
- 239000005023 polychlorotrifluoroethylene (PCTFE) polymer Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001195 polyisoprene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000306 polymethylpentene Polymers 0.000 description 1
- 239000011116 polymethylpentene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 235000003499 redwood Nutrition 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 230000037425 regulation of transcription Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000011524 similarity measure Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 238000012706 support-vector machine Methods 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161435922P | 2011-01-25 | 2011-01-25 | |
| US61/435,922 | 2011-01-25 | ||
| PCT/US2012/022594 WO2012103250A2 (en) | 2011-01-25 | 2012-01-25 | Colon cancer gene expression signatures and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20140006898A true KR20140006898A (ko) | 2014-01-16 |
Family
ID=46581385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020137021973A Withdrawn KR20140006898A (ko) | 2011-01-25 | 2012-01-25 | 결장암 유전자 발현 시그니처 및 이용 방법 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10196691B2 (enExample) |
| EP (1) | EP2668296B1 (enExample) |
| JP (1) | JP2014509189A (enExample) |
| KR (1) | KR20140006898A (enExample) |
| CN (1) | CN103403543B9 (enExample) |
| AU (1) | AU2012209074A1 (enExample) |
| BR (1) | BR112013018924A2 (enExample) |
| CA (1) | CA2825218A1 (enExample) |
| EA (1) | EA201391074A1 (enExample) |
| IL (1) | IL227643A0 (enExample) |
| MX (1) | MX2013008367A (enExample) |
| SG (1) | SG192108A1 (enExample) |
| WO (1) | WO2012103250A2 (enExample) |
| ZA (1) | ZA201305024B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2556171E (pt) | 2010-04-05 | 2015-12-21 | Prognosys Biosciences Inc | Ensaios biológicos codificados espacialmente |
| US10787701B2 (en) | 2010-04-05 | 2020-09-29 | Prognosys Biosciences, Inc. | Spatially encoded biological assays |
| US20190300945A1 (en) | 2010-04-05 | 2019-10-03 | Prognosys Biosciences, Inc. | Spatially Encoded Biological Assays |
| GB201106254D0 (en) | 2011-04-13 | 2011-05-25 | Frisen Jonas | Method and product |
| US20130074201A1 (en) * | 2011-09-16 | 2013-03-21 | The Johns Hopkins University | Cancer-specific genetic rearrangements |
| DK3511423T4 (da) * | 2012-10-17 | 2024-07-29 | Spatial Transcriptomics Ab | Fremgangsmåder og produkt til optimering af lokaliseret eller rumlig detektion af genekspression i en vævsprøve |
| EP4234716A3 (en) | 2013-06-25 | 2023-12-06 | Prognosys Biosciences, Inc. | Methods for determining spatial patterns of biological targets in a sample |
| US9652722B1 (en) * | 2013-12-05 | 2017-05-16 | The Mathworks, Inc. | Methods and systems for robust supervised machine learning |
| WO2015121465A1 (en) * | 2014-02-17 | 2015-08-20 | Ventana Medical Systems, Inc. | G-alpha, interacting vesicle associated protein (giv) as a predictive marker in stage ii colorectal cancer |
| CN106460047B (zh) * | 2014-04-10 | 2019-11-26 | 比奥马卡尔技术有限公司 | 用于鉴定癌前结肠直肠息肉和结肠直肠癌的方法及试剂盒 |
| EP4119677B1 (en) | 2015-04-10 | 2023-06-28 | Spatial Transcriptomics AB | Spatially distinguished, multiplex nucleic acid analysis of biological specimens |
| CN108020672A (zh) * | 2016-11-03 | 2018-05-11 | 中国医学科学院基础医学研究所 | 检测rhbdd1蛋白的elisa方法及试剂盒 |
| WO2018107023A1 (en) * | 2016-12-08 | 2018-06-14 | Dana-Farber Cancer Institute, Inc. | Metabolic profiling of fixed samples |
| CN107158388B (zh) * | 2017-07-11 | 2021-03-23 | 上海市第一人民医院 | MIIP pS303阻断剂在制备抗肿瘤药物中的应用 |
| EP3743534B1 (en) * | 2018-01-22 | 2022-03-23 | Liquid Biopsy Research LLC | Methods for colon cancer detection and treatment monitoring |
| AU2019252672B2 (en) * | 2018-04-12 | 2025-08-14 | Board Of Regents, The University Of Texas System | Biomarker for detecting cancer |
| JP2020028278A (ja) * | 2018-08-24 | 2020-02-27 | 国立大学法人九州大学 | 被検体に生じるイベントを予測するための判別器の生成方法、及び前記判別器を用いた被検体の層別化方法 |
| CN111321220A (zh) * | 2018-12-14 | 2020-06-23 | 中国医学科学院肿瘤医院 | 用于检测直肠癌放化疗敏感性的组合物、微阵列和计算机系统 |
| CN110079607B (zh) * | 2019-04-04 | 2022-08-02 | 陕西师范大学 | 一种引物组、检测血液样品种属的方法及应用 |
| EP3976820A1 (en) | 2019-05-30 | 2022-04-06 | 10X Genomics, Inc. | Methods of detecting spatial heterogeneity of a biological sample |
| WO2021247568A1 (en) | 2020-06-02 | 2021-12-09 | 10X Genomics, Inc. | Spatial trancriptomics for antigen-receptors |
| EP4025692A2 (en) | 2020-06-02 | 2022-07-13 | 10X Genomics, Inc. | Nucleic acid library methods |
| ES2981265T3 (es) | 2020-06-08 | 2024-10-08 | 10X Genomics Inc | Métodos para determinar un margen quirúrgico y métodos de uso del mismo |
| WO2022002873A1 (en) * | 2020-06-30 | 2022-01-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies |
| CN111951883A (zh) * | 2020-08-04 | 2020-11-17 | 广东省第二人民医院（广东省卫生应急医院） | 一种特征mRNA表达谱组合及结肠癌早期预测方法 |
| CN115786518A (zh) * | 2022-11-29 | 2023-03-14 | 广东医科大学附属医院 | 嗅素结构域家族蛋白4（olfm4）在结肠癌检测产品中的应用 |
| WO2024206495A2 (en) * | 2023-03-27 | 2024-10-03 | Immunis.Ai, Inc. | Active surveillance and risk stratification for prostate cancer |
| CN119372311A (zh) * | 2024-09-30 | 2025-01-28 | 东南大学 | 基于成纤维细胞相关基因的结肠癌预后和治疗抵抗预测模型的构建方法和应用 |
| CN120009551B (zh) * | 2025-02-27 | 2025-08-15 | 西南医科大学 | 剪接因子wbp11及其抑制剂的用途、预防或治疗结直肠癌的药物 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU575586B2 (en) | 1983-09-02 | 1988-08-04 | Syngene, Inc. | Oligonucleotide synthesis employing primer with oxidzable substituents in system |
| CA1323293C (en) | 1987-12-11 | 1993-10-19 | Keith C. Backman | Assay using template-dependent nucleic acid probe reorganization |
| GB8810400D0 (en) | 1988-05-03 | 1988-06-08 | Southern E | Analysing polynucleotide sequences |
| JP2955759B2 (ja) | 1988-07-20 | 1999-10-04 | セゲブ・ダイアグノスティックス・インコーポレイテッド | 核酸配列を増幅及び検出する方法 |
| US5219727A (en) | 1989-08-21 | 1993-06-15 | Hoffmann-Laroche Inc. | Quantitation of nucleic acids using the polymerase chain reaction |
| US5427930A (en) | 1990-01-26 | 1995-06-27 | Abbott Laboratories | Amplification of target nucleic acids using gap filling ligase chain reaction |
| US5554501A (en) | 1992-10-29 | 1996-09-10 | Beckman Instruments, Inc. | Biopolymer synthesis using surface activated biaxially oriented polypropylene |
| US5538848A (en) | 1994-11-16 | 1996-07-23 | Applied Biosystems Division, Perkin-Elmer Corp. | Method for detecting nucleic acid amplification using self-quenching fluorescence probe |
| US5648211A (en) | 1994-04-18 | 1997-07-15 | Becton, Dickinson And Company | Strand displacement amplification using thermophilic enzymes |
| DE69503126T2 (de) | 1994-05-05 | 1998-11-12 | Beckman Instruments Inc | Repetitive oligonukleotide matrix |
| WO1996002668A1 (en) | 1994-07-15 | 1996-02-01 | Azco Nobel N.V. | Use of rna polymerase to improve nucleic acid amplification process |
| AT402203B (de) | 1995-06-13 | 1997-03-25 | Himmler Gottfried Dipl Ing Dr | Verfahren zur transkriptionsfreien amplifizierung von nucleinsäuren |
| US5716784A (en) | 1996-02-05 | 1998-02-10 | The Perkin-Elmer Corporation | Fluorescence detection assay for homogeneous PCR hybridization systems |
| EP2369007B1 (en) | 1996-05-29 | 2015-07-29 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions |
| US5985567A (en) | 1997-08-15 | 1999-11-16 | Beckman Coulter, Inc. | Hybridization detection by pretreating bound single-stranded probes |
| US6013789A (en) | 1998-02-20 | 2000-01-11 | Beckman Coulter, Inc. | Covalent attachment of biomolecules to derivatized polypropylene supports |
| AU2001252945A1 (en) | 2000-03-24 | 2001-10-08 | Corixa Corporation | Compositions and methods for therapy and diagnosis of colon cancer |
| US20060046249A1 (en) | 2002-01-18 | 2006-03-02 | Fei Huang | Identification of polynucleotides and polypetide for predicting activity of compounds that interact with protein tyrosine kinase and or protein tyrosine kinase pathways |
| DK2284266T3 (da) | 2002-11-14 | 2014-01-13 | Thermo Fisher Scient Biosciences Inc | sIRNA-MOLEKYLE MOD TP53 |
| US7250496B2 (en) * | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
| US20040146921A1 (en) | 2003-01-24 | 2004-07-29 | Bayer Pharmaceuticals Corporation | Expression profiles for colon cancer and methods of use |
| US20050287544A1 (en) * | 2003-12-01 | 2005-12-29 | Francois Bertucci | Gene expression profiling of colon cancer with DNA arrays |
| JP2008504803A (ja) * | 2004-01-09 | 2008-02-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 遺伝子発現の細胞型特異的パターン |
| US20060195266A1 (en) | 2005-02-25 | 2006-08-31 | Yeatman Timothy J | Methods for predicting cancer outcome and gene signatures for use therein |
| WO2005083128A2 (en) | 2004-02-25 | 2005-09-09 | University Of South Florida | Methods for predicting cancer outcome and gene signatures for use therein |
| JP2008504018A (ja) | 2004-06-03 | 2008-02-14 | ジョンズ ホプキンス ユニバーシティ | 細胞増殖または新生物性障害に関してスクリーニングする方法 |
| AU2005300688B2 (en) | 2004-11-03 | 2012-02-02 | Almac Diagnostics Limited | Transcriptome microarray technology and methods of using the same |
| TW200730825A (en) * | 2005-10-21 | 2007-08-16 | Genenews Inc | Method and apparatus for correlating levels of biomarker products with disease |
| KR20090003178A (ko) * | 2006-01-11 | 2009-01-09 | 게노믹 헬쓰, 인코포레이티드 | 직장결장암 예후에 대한 유전자 발현 마커 |
| WO2007112330A2 (en) | 2006-03-24 | 2007-10-04 | Diadexus, Inc. | Compositions and methods for detection, prognosis and treatment of colon cancer |
| US20100261169A1 (en) * | 2007-01-29 | 2010-10-14 | Shira Wallach | Novel nucleotide and amino acid sequences, and methods of use thereof for diagnosis |
| NZ562237A (en) * | 2007-10-05 | 2011-02-25 | Pacific Edge Biotechnology Ltd | Proliferation signature and prognosis for gastrointestinal cancer |
| WO2009147537A2 (en) | 2008-05-27 | 2009-12-10 | Dako Denmark A/S | Compositions and methods for detection of chromosomal aberrations with novel hybridization buffers |
| WO2010060055A1 (en) | 2008-11-21 | 2010-05-27 | Duke University | Predicting cancer risk and treatment success |
-
2012
- 2012-01-25 AU AU2012209074A patent/AU2012209074A1/en not_active Abandoned
- 2012-01-25 JP JP2013551314A patent/JP2014509189A/ja active Pending
- 2012-01-25 MX MX2013008367A patent/MX2013008367A/es unknown
- 2012-01-25 EA EA201391074A patent/EA201391074A1/ru unknown
- 2012-01-25 CN CN201280010123.2A patent/CN103403543B9/zh not_active Expired - Fee Related
- 2012-01-25 SG SG2013056254A patent/SG192108A1/en unknown
- 2012-01-25 US US13/981,601 patent/US10196691B2/en not_active Expired - Fee Related
- 2012-01-25 CA CA2825218A patent/CA2825218A1/en not_active Abandoned
- 2012-01-25 WO PCT/US2012/022594 patent/WO2012103250A2/en not_active Ceased
- 2012-01-25 EP EP12739742.0A patent/EP2668296B1/en not_active Not-in-force
- 2012-01-25 BR BR112013018924A patent/BR112013018924A2/pt not_active IP Right Cessation
- 2012-01-25 KR KR1020137021973A patent/KR20140006898A/ko not_active Withdrawn
-
2013
- 2013-07-04 ZA ZA2013/05024A patent/ZA201305024B/en unknown
- 2013-07-24 IL IL227643A patent/IL227643A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2668296A4 (en) | 2015-09-02 |
| CN103403543B (zh) | 2016-11-09 |
| AU2012209074A1 (en) | 2013-07-11 |
| EA201391074A1 (ru) | 2013-12-30 |
| IL227643A0 (en) | 2013-09-30 |
| US10196691B2 (en) | 2019-02-05 |
| BR112013018924A2 (pt) | 2018-05-08 |
| SG192108A1 (en) | 2013-08-30 |
| ZA201305024B (en) | 2014-03-26 |
| CN103403543B9 (zh) | 2017-05-17 |
| WO2012103250A3 (en) | 2012-10-11 |
| EP2668296B1 (en) | 2018-08-15 |
| EP2668296A2 (en) | 2013-12-04 |
| US20140094379A1 (en) | 2014-04-03 |
| JP2014509189A (ja) | 2014-04-17 |
| CA2825218A1 (en) | 2012-08-02 |
| CN103403543A (zh) | 2013-11-20 |
| MX2013008367A (es) | 2013-08-12 |
| NZ612471A (en) | 2015-11-27 |
| WO2012103250A2 (en) | 2012-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20140006898A (ko) | 결장암 유전자 발현 시그니처 및 이용 방법 | |
| AU2019201577B2 (en) | Cancer diagnostics using biomarkers | |
| CN109790583B (zh) | 对肺腺癌亚型分型的方法 | |
| DK2681333T3 (en) | EVALUATION OF RESPONSE TO GASTROENTEROPANCREATIC NEUROENDOCRINE NEOPLASIS (GEP-NENE) THERAPY | |
| AU2018210695B2 (en) | Molecular subtyping, prognosis, and treatment of bladder cancer | |
| US10889865B2 (en) | Thyroid tumors identified | |
| CN109863251B (zh) | 对肺鳞状细胞癌亚型分型的方法 | |
| DK2644712T3 (en) | A method for diagnosing neoplasms | |
| RU2721916C2 (ru) | Способы прогнозирования рака предстательной железы | |
| KR20140044341A (ko) | 암에 대한 분자적 진단 검사 | |
| KR20150090246A (ko) | 암을 위한 분자 진단 테스트 | |
| KR20160052729A (ko) | 폐암에 대한 분자적 진단 검사 | |
| KR20160117606A (ko) | 항-혈관형성 약물에 대한 반응 및 암의 예후를 예측하기 위한 분자적 진단 시험 | |
| KR20110057188A (ko) | 바이오마커 프로파일 측정 시스템 및 방법 | |
| CN101573453A (zh) | 使用生物学途径基因表达分析来预测淋巴结阴性原发性乳腺癌的远处转移的方法 | |
| CN101258249A (zh) | 检测黑素瘤的方法和试剂 | |
| AU2020201779B2 (en) | Method for using gene expression to determine prognosis of prostate cancer | |
| AU2018304242A1 (en) | Methods for detection of plasma cell dyscrasia | |
| CN108841823A (zh) | circRNA_26852及其应用 | |
| CN101111768A (zh) | 肺癌预后 | |
| KR102480128B1 (ko) | 면역력 강화 소 African Humped Cattle (AFH) 품종 특이적 단일염기다형성 및 그의 용도 | |
| AU2004205270B2 (en) | Colorectal cancer prognostics | |
| US20030175761A1 (en) | Identification of genes whose expression patterns distinguish benign lymphoid tissue and mantle cell, follicular, and small lymphocytic lymphoma | |
| US20030175704A1 (en) | Genes expressed in lung cancer | |
| KR102631854B1 (ko) | Bub1의 비근침윤성 방광암의 예후 예측용 바이오마커로의 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20130820 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |